EMA and HTA Bodies Launch Three-Year Plan To Better Understand Each Other’s Needs
Executive Summary
Understanding how the EMA defines therapeutic indications and how this affects the definition of the treatment-eligible population by HTA bodies is one of the many goals of a new joint workplan by the agency and the EUnetHTA.
You may also be interested in...
Single Gateway For EMA-HTA Advice May Answer All Stakeholders’ Needs
The EU research-based pharmaceutical industry has welcomed the launch of a new single gateway for companies to seek parallel scientific advice from the European Medicines Agency and health technology assessment bodies on initial evidence generation and post-authorization data collection. The industry hopes the initiative will help deliver one single evidence package for regulatory and HTA purposes.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.
EU CHMP Opinions And MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.